Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Zymeworks stock price, quote, forecast and news

ZYME
CA98985W1023
A2DP0F

Price

11.56
Today +/-
-0.18
Today %
-1.72 %
P

Zymeworks stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zymeworks stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zymeworks stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zymeworks stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zymeworks's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zymeworks Stock Price History

DateZymeworks Price
9/6/202411.56 undefined
9/5/202411.76 undefined
9/4/202411.59 undefined
9/3/202411.52 undefined
8/30/202411.73 undefined
8/29/202411.72 undefined
8/28/202411.38 undefined
8/27/202411.57 undefined
8/26/202411.54 undefined
8/23/202411.39 undefined
8/22/202411.16 undefined
8/21/202411.10 undefined
8/20/202410.87 undefined
8/19/202410.49 undefined
8/16/202410.48 undefined
8/15/202410.50 undefined
8/14/202410.14 undefined
8/13/202410.23 undefined
8/12/202410.36 undefined

Zymeworks Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zymeworks, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zymeworks from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zymeworks’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zymeworks. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zymeworks’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zymeworks’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zymeworks’s growth potential.

Zymeworks Revenue, EBIT and net profit per share

DateZymeworks RevenueZymeworks EBITZymeworks Net Income
2029e199.43 M undefined0 undefined-4.71 M undefined
2028e120.05 M undefined-95.22 M undefined-57.25 M undefined
2027e112.41 M undefined-131.58 M undefined-79.23 M undefined
2026e145.74 M undefined-96.69 M undefined-87.93 M undefined
2025e148.27 M undefined-42.34 M undefined-63.77 M undefined
2024e111.17 M undefined-77.72 M undefined-80.29 M undefined
202376.01 M undefined-138.05 M undefined-118.67 M undefined
2022412.5 M undefined130.5 M undefined124.3 M undefined
202126.7 M undefined-215.6 M undefined-211.8 M undefined
202039 M undefined-187.5 M undefined-180.6 M undefined
201929.5 M undefined-150.5 M undefined-145.4 M undefined
201853 M undefined-33.4 M undefined-36.6 M undefined
201751.8 M undefined-7.4 M undefined-10.4 M undefined
201611 M undefined-37.1 M undefined-33.8 M undefined
20159.7 M undefined-20 M undefined-19.2 M undefined
20141.7 M undefined-12.7 M undefined-12.9 M undefined

Zymeworks Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
1911515329392641276111148145112120199
-800.0022.22363.643.92-45.2834.48-33.331,484.62-81.5546.0533.33-2.03-22.767.1465.83
----------------
0000000000000000
-12-20-37-7-33-150-187-215130-138-77-42-96-131-950
-1,200.00-222.22-336.36-13.73-62.26-517.24-479.49-826.9231.55-181.58-69.37-28.38-66.21-116.96-79.17-
-12-19-33-10-36-145-180-211124-118-80-63-87-79-57-4
-58.3373.68-69.70260.00302.7824.1417.22-158.77-195.16-32.20-21.2538.10-9.20-27.85-92.98
24.224.224.221.229.13850.451.665.268.86000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Zymeworks Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zymeworks is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
46.815.240.387.8200.2298.9426.4252.6492.2374.33
0.31.52.60.20.42.215.315.633.419.48
2.70.81.72.1000000
0000000000
0.20.31.92.23.810.713.42019.119.12
5017.846.592.3204.4311.8455.1288.2544.7412.93
0.50.86.77.26.516.517.649.847.737.54
04.2000025.90.90.982.15
0000000000
0.10.120.619.12023.722.921.526.425.28
001212121212121212.02
00.48.11.31.64.24.816.817.110.96
0.65.547.439.640.156.483.2101104.1167.95
50.623.393.9131.9244.5368.2538.3389.2648.8580.88
                   
0.080.080.170.220.320.450.720.740.911.01
3.54.96.98.812.392.8163.6197.7151.6142.27
-44.4-63.6-97.8-108.7-145.3-290.7-471.3-683.1-558.8-677.44
-1.1-6.7-6.7-6.7-6.7-6.7-6.7-6.7-6.7-6.6
0000000000
39.718.267.9116.4180.4245.6409.8249492.9464.81
1.82.131.72.65.36.25.27.96.21
1.12.65.4710.130.83956.781.140.78
80.18.1617.346.440.4106.78.74
0000000000
00000000030
10.94.816.514.73082.585.671.995.755.76
004.40000.10.10.10.09
00500.10.41.21.61.83.3
000.10.933.839.541.566.558.256.92
009.50.933.939.942.868.260.160.31
10.94.82615.663.9122.4128.4140.1155.8116.07
50.62393.9132244.3368538.2389.1648.7580.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zymeworks provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zymeworks's financial health and stability.

Assets

Zymeworks's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zymeworks must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zymeworks after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zymeworks's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-12-19-33-10-36-145-180-211124-118
00123576710
00-5,0000000-1,0001,0000
4-4-21396-1004-25
12993010160241024
0000000000
0000000000
-7-22-35024-81-151-192144-118
00-5-3-3-13-6-13-13-4
0-9-25-30-109-25-43144-53-207
0-8-20-27-105-11-37157-40-203
0000000000
006-7000000
461585791194309810932
461645091193309810881
00-100000049
0000000000
37-35419686113-40199-243
-7.3-23.1-40.7-2.920.8-95.8-157.7-205.8131-122.38
0000000000

Zymeworks stock margins

The Zymeworks margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zymeworks. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zymeworks.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zymeworks's sales revenue. A higher gross margin percentage indicates that the Zymeworks retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zymeworks's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zymeworks's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zymeworks's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zymeworks. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zymeworks's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zymeworks Margin History

Zymeworks Gross marginZymeworks Profit marginZymeworks EBIT marginZymeworks Profit margin
2029e0 %0 %-2.36 %
2028e0 %-79.31 %-47.69 %
2027e0 %-117.05 %-70.49 %
2026e0 %-66.34 %-60.33 %
2025e0 %-28.55 %-43.01 %
2024e0 %-69.91 %-72.22 %
20230 %-181.62 %-156.13 %
20220 %31.64 %30.13 %
20210 %-807.49 %-793.26 %
20200 %-480.77 %-463.08 %
20190 %-510.17 %-492.88 %
20180 %-63.02 %-69.06 %
20170 %-14.29 %-20.08 %
20160 %-337.27 %-307.27 %
20150 %-206.19 %-197.94 %
20140 %-747.06 %-758.82 %

Zymeworks Stock Sales Revenue, EBIT, Earnings per Share

The Zymeworks earnings per share therefore indicates how much revenue Zymeworks has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zymeworks earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zymeworks's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zymeworks’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zymeworks's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zymeworks Revenue, EBIT and net profit per share

DateZymeworks Sales per ShareZymeworks EBIT per shareZymeworks Earnings per Share
2029e2.81 undefined0 undefined-0.07 undefined
2028e1.69 undefined0 undefined-0.81 undefined
2027e1.58 undefined0 undefined-1.12 undefined
2026e2.05 undefined0 undefined-1.24 undefined
2025e2.09 undefined0 undefined-0.9 undefined
2024e1.56 undefined0 undefined-1.13 undefined
20231.1 undefined-2 undefined-1.72 undefined
20226.33 undefined2 undefined1.91 undefined
20210.52 undefined-4.18 undefined-4.1 undefined
20200.77 undefined-3.72 undefined-3.58 undefined
20190.78 undefined-3.96 undefined-3.83 undefined
20181.82 undefined-1.15 undefined-1.26 undefined
20172.44 undefined-0.35 undefined-0.49 undefined
20160.45 undefined-1.53 undefined-1.4 undefined
20150.4 undefined-0.83 undefined-0.79 undefined
20140.07 undefined-0.52 undefined-0.53 undefined

Zymeworks business model

Zymeworks Inc is a biotechnology company that was founded in 2003. The company is headquartered in Vancouver, Canada. The founders of the company were a group of researchers specializing in the development of antibodies. Their goal was to develop a platform technology that allows for the design and production of highly specific and effective antibodies. Zymeworks Inc's platform technology is based on the use of protein engineering technologies such as Immunoglobulin G competences (IgG). This allows for the targeted production of antibodies that bind to specific target molecules. The business model of Zymeworks Inc is based on licensing its platform technology to other companies. The licensees use Zymeworks' platform to develop antibodies or other proteins for their own pharmaceutical research. Zymeworks Inc has various business areas that specialize in the different applications of its platform technology. This includes cancer immunotherapy, the treatment of autoimmune diseases, and the development of biological therapeutics. The company also offers products that can be used directly by patients, such as a test kit for determining the risk of breast cancer. Over the years, Zymeworks Inc has expanded its business areas and formed partnerships with major pharmaceutical companies. In summary, Zymeworks Inc is a leading biotechnology company specializing in the development of antibodies and other proteins. It has a unique platform technology that allows its customers to develop targeted antibodies and therapeutic proteins. Its products are used in various areas, including cancer immunotherapy, the treatment of autoimmune diseases, and biological therapeutics. Zymeworks is one of the most popular companies on Eulerpool.com.

Zymeworks SWOT Analysis

Strengths

1. Diverse pipeline of next-generation bi-specific and multi-specific antibody therapeutics.

2. Strong intellectual property portfolio and innovative proprietary technology platforms.

3. Well-established collaborations with leading pharmaceutical companies.

Weaknesses

1. High dependence on key partnership agreements, posing risks in case of termination or failure.

2. Relatively small size compared to established competitors, limiting resources and market reach.

3. Limited therapeutic candidates in late-stage clinical development.

Opportunities

1. Growing global market for targeted cancer therapies, providing opportunities for expansion.

2. Increasing investment in biopharmaceutical research and development.

3. Potential for strategic partnerships with biotechnology or pharmaceutical companies.

Threats

1. Intense competition from well-established and financially strong pharmaceutical companies.

2. Stringent regulatory requirements for drug development and approval.

3. Risks associated with clinical trials, including safety concerns and failure to meet endpoints.

Zymeworks Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zymeworks historical P/E ratio, EBIT, and P/S ratio.

Zymeworks shares outstanding

The number of shares was Zymeworks in 2023 — This indicates how many shares 68.863 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zymeworks earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zymeworks's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zymeworks’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zymeworks's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Zymeworks.

Zymeworks list of shareholders

%
Name
Stocks
Change
Date
8.12386 % Armistice Capital LLC5,772,00012,0006/30/2022
8.10449 % Redmile Group, LLC5,758,2411,922,4238/5/2022
7.57241 % Eventide Asset Management, LLC5,380,20006/30/2022
5.81637 % Perceptive Advisors LLC4,132,534-1,193,0816/30/2022
5.22097 % All Blue Falcons FZE3,709,498570,0005/26/2022
3.43842 % Credit Suisse Asset Management2,442,997-31,5696/30/2022
2.81492 % Camber Capital Management LP2,000,00006/30/2022
2.50237 % Morgan Stanley & Co. LLC1,777,932-375,1406/30/2022
2.40461 % Baker Bros. Advisors LP1,708,47206/30/2022
2.31087 % Woodline Partners LP1,641,876-574,1866/30/2022
1
2
3
4
5
...
10

Zymeworks Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck & Co Stock
Merck & Co
SupplierCustomer0,67-0,30-0,51-0,59-0,49-0,46
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,53-0,18-0,590,02-0,430,40
BeiGene Stock
BeiGene
SupplierCustomer0,470,600,400,880,770,35
Eli Lilly Stock
Eli Lilly
SupplierCustomer0,39-0,07-0,14-0,41-0,62-0,76
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,270,40-0,54-0,41-0,84-0,71
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,08-0,48-0,53-0,85-0,42-0,49
Pfizer Stock
Pfizer
SupplierCustomer-0,120,44-0,190,44-0,74-0,78
ALX Oncology Holdings Stock
ALX Oncology Holdings
SupplierCustomer-0,260,510,590,790,92-
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,61-0,36-0,58-0,62-0,28-0,63
1

Most common questions regarding Zymeworks

What values and corporate philosophy does Zymeworks represent?

Zymeworks Inc represents values of innovation, collaboration, and scientific excellence. As a biopharmaceutical company, Zymeworks is committed to developing breakthrough therapies to improve the lives of patients. The company's corporate philosophy revolves around leveraging its proprietary drug discovery platform and advanced protein engineering capabilities. By focusing on developing multifunctional therapeutics, Zymeworks aims to address unmet medical needs and deliver transformative treatments in oncology and other disease areas. With a strong emphasis on research and development, Zymeworks strives to revolutionize the field of biotechnology and contribute to advancements in patient care.

In which countries and regions is Zymeworks primarily present?

Zymeworks Inc is primarily present in several countries and regions. As a global biopharmaceutical company, Zymeworks operates in the United States, Canada, and Europe. With its headquarters based in Vancouver, Canada, Zymeworks has expanded its presence in major pharmaceutical markets, including the United States and various European countries. Being renowned for its innovative drug discovery and development technologies, Zymeworks has established collaborations with partners worldwide, contributing to its international presence and reach within the biopharmaceutical industry.

What significant milestones has the company Zymeworks achieved?

Zymeworks Inc, a leading biopharmaceutical company, has achieved numerous significant milestones. Over the years, the company has successfully advanced its proprietary Azymetric™ and EFECT™ platforms, revolutionizing the development of bispecific antibodies for various therapeutic areas. Some notable achievements include the partnership with leading pharmaceutical companies, such as Merck and Eli Lilly, for the development of multiple therapies. Zymeworks Inc has also received regulatory approvals and achieved clinical development milestones for its investigational drugs, showcasing its dedication to improving patient care. These milestones underline Zymeworks Inc's commitment to innovation and its relentless pursuit of breakthrough treatments in the field of biopharmaceuticals.

What is the history and background of the company Zymeworks?

Zymeworks Inc, a leading biopharmaceutical company, was founded in 2003 in Vancouver, Canada. The company specializes in the development of innovative, protein-based therapeutics for the treatment of cancer and other diseases. With a strong focus on antibody engineering, Zymeworks has developed proprietary platforms that enable the design and optimization of therapeutic antibodies. Over the years, Zymeworks has established collaborations with global pharmaceutical companies, leveraging its technology to advance drug discovery and development efforts. With a dedicated team of experts and a robust pipeline of potential therapies, Zymeworks Inc continues to make significant contributions to the field of biopharmaceuticals.

Who are the main competitors of Zymeworks in the market?

The main competitors of Zymeworks Inc in the market include large pharmaceutical companies such as Amgen, Roche, Novartis, and Bristol-Myers Squibb. These companies are also actively involved in the field of biotechnology and drug development.

In which industries is Zymeworks primarily active?

Zymeworks Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Zymeworks?

The business model of Zymeworks Inc is focused on the development of multifunctional biotherapeutics using its proprietary Azymetric™ and EFECT™ platforms. The company leverages these platforms to create novel antibody-based drug candidates with enhanced characteristics, such as increased potency and multi-targeting capabilities. Zymeworks aims to address unmet medical needs across various therapeutic areas, including oncology, autoimmune, and inflammatory diseases. By employing its innovative platforms, Zymeworks aims to bring differentiated and effective treatments to patients, while also collaborating with leading biopharmaceutical companies to advance its pipeline.

What is the P/E ratio of Zymeworks 2024?

The Zymeworks P/E ratio is -9.92.

What is the P/S ratio of Zymeworks 2024?

The Zymeworks P/S ratio is 7.16.

What is the AlleAktien quality score of Zymeworks?

The AlleAktien quality score for Zymeworks is 3/10.

What is the revenue of Zymeworks 2024?

The expected Zymeworks revenue is 111.17 M USD.

How high is the profit of Zymeworks 2024?

The expected Zymeworks profit is -80.29 M USD.

What is the business model of Zymeworks

Zymeworks Inc specializes in developing therapeutics for patients with cancer and immune disorders. The company aims to transform the treatment of these patients by using innovative technologies and science to create tailored and precise solutions for their needs. Zymeworks' business model consists of two main divisions - therapeutic development and biotechnology platform development. The company offers various products and services within these divisions. Therapeutic development focuses on developing an innovative oncology portfolio of novel multi-specific antibody fragments. The company's therapeutic products aim to precisely recognize and destroy cancer cells. Currently, the company is working on the development of 6 lead candidates in the preclinical and clinical development phase. An example of this is Novartis' leading product, Kymriah®, which was developed in collaboration with Zymeworks. This product has been approved by the FDA and is now a widely used treatment for specific types of cancer. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties in a technically sophisticated manner. Zymeworks' product range is diverse and continuously expanding. In platform development, Zymeworks provides access to various biopharmaceutical expertise, such as protein engineering, fusion design, high-throughput screening, and animal modeling. Building on comprehensive experience and recognized capabilities in protein engineering design, Zymeworks offers a full spectrum of common and innovative biopharmaceutical development technologies. In conclusion, Zymeworks Inc is a company committed to improving the quality of life for patients with cancer and immune disorders. The company is active in therapeutic development through the development of novel multi-specific antibody fragments in the preclinical and clinical development phases. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties. The company offers a variety of products and services that are continuously expanding and supports its customers in the development of new and innovative medications. Answer: Zymeworks Inc specializes in developing therapeutics for cancer and immune disorders using innovative technologies and science. They have two main divisions - therapeutic development and biotechnology platform development. They offer various products and services in these areas.

What is the Zymeworks dividend?

Zymeworks pays a dividend of 0 USD distributed over payouts per year.

How often does Zymeworks pay dividends?

The dividend cannot currently be calculated for Zymeworks or the company does not pay out a dividend.

What is the Zymeworks ISIN?

The ISIN of Zymeworks is CA98985W1023.

What is the Zymeworks WKN?

The WKN of Zymeworks is A2DP0F.

What is the Zymeworks ticker?

The ticker of Zymeworks is ZYME.

How much dividend does Zymeworks pay?

Over the past 12 months, Zymeworks paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zymeworks is expected to pay a dividend of 0 USD.

What is the dividend yield of Zymeworks?

The current dividend yield of Zymeworks is .

When does Zymeworks pay dividends?

Zymeworks pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zymeworks?

Zymeworks paid dividends every year for the past 0 years.

What is the dividend of Zymeworks?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zymeworks located?

Zymeworks is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zymeworks kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zymeworks from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Zymeworks pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Zymeworks in the year 2023?

In the year 2023, Zymeworks distributed 0 USD as dividends.

In which currency does Zymeworks pay out the dividend?

The dividends of Zymeworks are distributed in USD.

All fundamentals about Zymeworks

Our stock analysis for Zymeworks Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zymeworks Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.